Sakamakon yana da kyau ga masu haɓaka gwajin antigen, waɗanda suka ga raguwar buƙata bayan ƙaddamar da maganin.
Wani karamin binciken da Cibiyar Kiwon Lafiya ta Kasa (NIS) ta bayar ya gano cewa gwajin kwararar ruwa na Covid-19 (LFT) yana da tasiri kamar gwajin sarkar polymerase (PCR) wajen gano kamuwa da cutar SARS-CoV-2.Ana yin shi a kowane kwana uku ana dubawa ɗaya.
Ana ɗaukar gwaje-gwajen PCR a matsayin ma'aunin zinare don bincikar kamuwa da cutar ta Covid-19, amma yawan amfani da su azaman kayan aikin tantancewa yana iyakance saboda suna buƙatar sarrafa su a cikin dakin gwaje-gwaje kuma sakamakon na iya ɗaukar kwanaki da yawa don isa ga marasa lafiya.
Sabanin haka, LFT na iya ba da sakamako a cikin ɗan mintuna 15, kuma masu amfani ba sa ma buƙatar barin gida.
Masu binciken da ke da alaƙa da NIH Diagnostic Rapid Acceleration Programme sun ba da rahoton sakamakon mutane 43 da suka kamu da Covid-19.Mahalarta taron sun fito ne daga Jami'ar Illinois a Urbana-Champaign (UIUC) SHIELD shirin gwajin Covid-19 na Illinois.Ko dai sun gwada da kansu ko kuma suna da kusanci da mutanen da suka gwada inganci.
An shigar da mahalarta cikin 'yan kwanaki da kamuwa da cutar, kuma sakamakon gwajin ya kasance mara kyau a cikin kwanaki 7 kafin shiga.
Dukkansu sun ba da samfurin miya da nau'i biyu na swabs na hanci don kwanaki 14 a jere, wanda PCR, LFT, da al'adun ƙwayoyin cuta masu rai suka sarrafa su.
Noman ƙwayoyin cuta tsari ne mai matuƙar aiki da tsada wanda ba a amfani da shi a gwajin Covid-19 na yau da kullun, amma yana taimakawa sosai don tantance yanayin ƙwayar cuta daga samfurin.Wannan na iya taimaka wa masu bincike ƙididdige farawa da tsawon lokacin yaduwar Covid-19.
Christopher Brooke, Farfesa na Molecular and Cell Biology a UIUC, ya ce: “Mafi yawan gwaje-gwajen suna gano kwayoyin halittar da ke da alaka da kwayar cutar, amma wannan ba ya nufin cewa akwai kwayar cuta mai rai.Hanya daya tilo da za a tantance ko akwai kwayar cuta mai rai, mai kamuwa da cuta ita ce aiwatar da kayyade cutar ko kuma al'ada. "
Bayan haka, masu binciken sun kwatanta hanyoyin gano ƙwayoyin cuta guda uku na Covid-19-Gano PCR na miya, gano PCR na samfuran hanci, da saurin gano samfuran antigen na Covid-19 na samfuran hanci.
Ana yin sakamakon samfurin salwa ta hanyar gwajin PCR da aka ba da izini dangane da miya da UIUC ta haɓaka, wanda ake kira covidSHIELD, wanda zai iya samar da sakamako bayan kusan awanni 12.Ana amfani da gwajin PCR daban ta amfani da na'urar Abbott Alinity don samun sakamako daga swabs na hanci.
An yi saurin gano antigen ta amfani da Quidel Sofia SARS antigen fluorescence immunoassay, LFT, wanda aka ba da izini don kulawa nan da nan kuma yana iya haifar da sakamako bayan mintuna 15.
Bayan haka, masu binciken sun ƙididdige hankalin kowace hanya don gano SARS-CoV-2 kuma sun auna kasancewar kwayar cutar a cikin makonni biyu na kamuwa da cuta ta farko.
Sun gano cewa gwajin PCR ya fi hankali fiye da saurin gwajin antigen na Covid-19 lokacin gwajin cutar kafin lokacin kamuwa da cuta, amma sun nuna cewa sakamakon PCR na iya ɗaukar kwanaki da yawa don mayar da shi ga mutumin da ake gwadawa.
Masu binciken sun ƙididdige ƙimar gwajin dangane da mitar gwajin kuma sun gano cewa azancin gano kamuwa da cuta ya fi kashi 98% lokacin da ake yin gwajin kowane kwana uku, ko saurin gwajin antigen na Covid-19 ne ko kuma gwajin PCR.
Lokacin da suka kimanta mitar ganowa sau ɗaya a mako, ƙwarewar gano PCR ga kogon hanci da ɗigo har yanzu yana da girma, kusan 98%, amma ƙwarewar gano antigen ya ragu zuwa 80%.
Sakamakon ya nuna cewa yin amfani da saurin gwajin antigen na Covid-19 aƙalla sau biyu a mako don gwajin Covid-19 yana da kwatankwacin aiki da gwajin PCR kuma yana haɓaka yuwuwar gano wanda ya kamu da cutar a farkon matakin cutar.
Wadannan sakamakon za a yi maraba da su ta hanyar masu haɓaka gwajin antigen, waɗanda kwanan nan suka ba da rahoton cewa buƙatar gwajin Covid-19 ya ragu saboda ƙaddamar da rigakafin.
Dukansu tallace-tallacen BD da Quidel a cikin sabbin abubuwan da aka samu sun yi ƙasa da tsammanin masu sharhi, kuma bayan buƙatun gwajin Covid-19 ya faɗi sosai, Abbott ya rage hasashen sa na 2021.
Yayin barkewar cutar, likitocin sun yi sabani kan ingancin LFT, musamman don manyan shirye-shiryen gwaji, saboda galibi suna yin rashin kyau wajen gano cututtukan asymptomatic.
Wani bincike da Cibiyar Kula da Cututtuka da Cututtuka ta Amurka ta buga a watan Janairu ya nuna cewa saurin gwajin Abbott BinaxNOW na iya rasa kusan kashi biyu bisa uku na cututtukan asymptomatic.
A lokaci guda kuma, gwajin Innova da aka yi amfani da shi a cikin Burtaniya ya nuna cewa hankali ga masu cutar Covid-19 masu cutarwa kashi 58% ne kawai, yayin da taƙaitaccen bayanan matukin jirgi ya nuna cewa asymptomatic hankali kashi 40 ne kawai.
Lokacin aikawa: Yuli-22-2021